Coronary artery disease is responsible for the sudden death of over 500,000 U.S. citizens per year. The development of biomarkers that predict increased risk of major adverse coronary events is a major public health need in the United States. Elevated plasma myeloperoxidase (MPO) levels have been shown to be a predictor of increased risk of coronary events in patients with acute coronary syndromes. MPO release from neutrophils precedes myocardial injury, and it has been suggested that MPO activity may mediate, in part, adverse coronary events. Accordingly, in comparison to plasma MPO levels, plasma levels of MPO-generated oxidation products may be better predictors of adverse coronary events. We have discovered 1-chloro-fatty aldehyde (1- ClFALD) as a novel MPO-generated lipid oxidation product. In the past year, we have revealed that 1-chloro- fatty acid (1-ClFA) and 1-chloro-fatty alcohol (1-ClFOH) are stable metabolites of 1-ClFALD that are released from neutrophils and are also present in human plasma. Accordingly, the specific aim of this proposal is to test the hypothesis that plasma levels of 1-ClFA and 1-ClFOH predict increased risk of major adverse coronary events in patients with coronary artery disease. An extensive clinical database and repository of human plasma specimens from a study called Genebank at the Cleveland Clinic Foundation will be available for these studies. Extensive clinical phenotypic data from subjects undergoing diagnostic cardiac catheterization are available for all subjects enrolled in this study. Complete medical history, laboratory, angiographic and outcomes data are available, and subjects have provided consent for use of these specimens and anonymonized clinical data to support biochemical research efforts related to cardiovascular disease. A case-cohort design will allow us to evaluate multiple outcomes using the same control population. The case definition will include subjects that suffered non-fatal myocardial infarction, stroke or death. Controls will be drawn from a random sample of age and gender-matched eligible subjects from the Genebank registry demonstrating no inter- vening history of cardiovascular disease. At Saint Louis University, plasma 1-ClFA will be quantified by LC-MS on a triple quadrupole instrument using electrospray ionization. Plasma 1-ClFOH will be quantified using GC- MS with negative ion-chemical ionization following derivatization to its pentafluorobenzoyl ester. Each analyte will be quantified by comparisons to synthetically-prepared deuterated internal standards. Comparisons will be made between levels of these new biomarkers to that of other biomarkers including C-reactive protein, MPO, chlorotyrosine, nitrotyrosine and troponin T that have previously been quantified in these specimens. The availability of these collected human samples in Genebank provides an extraordinary opportunity to identify these novel MPO-catalyzed oxidation products in the plasma of a focused and well-defined group of heart patients as novel biomarkers. Furthermore, this study will allow a direct measure of systemic MPO-catalyzed lipid oxidation for the first time and evaluation of its potential clinical relevance to cardiovascular disease.

Public Health Relevance

About 13 million U.S. citizens have coronary artery disease, and it is the leading cause of death among both men and women. In the proposed studies, we will test the hypothesis that plasma levels of novel MPO-generated lipid oxidation products predict major adverse coronary events. Identifying these novel lipid oxidation products as predictors of future major adverse coronary events has the potential to significantly impact care and outcomes of patients with coronary artery disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21HL088073-02
Application #
7597135
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Srinivas, Pothur R
Project Start
2008-04-01
Project End
2011-03-31
Budget Start
2009-04-01
Budget End
2011-03-31
Support Year
2
Fiscal Year
2009
Total Cost
$183,750
Indirect Cost
Name
Saint Louis University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
050220722
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Bowden, John A; Shao, Fei; Albert, Carolyn J et al. (2011) Electrospray ionization tandem mass spectrometry of sodiated adducts of cholesteryl esters. Lipids 46:1169-79
Bowden, John A; Ford, David A (2011) An examination of pentafluorobenzoyl derivatization strategies for the analysis of fatty alcohols using gas chromatography/electron capture negative ion chemical ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879:1375-83
Bowden, John A; Albert, Carolyn J; Barnaby, Omar S et al. (2011) Analysis of cholesteryl esters and diacylglycerols using lithiated adducts and electrospray ionization-tandem mass spectrometry. Anal Biochem 417:202-10
Anbukumar, Dhanalakshmi S; Shornick, Laurie P; Albert, Carolyn J et al. (2010) Chlorinated lipid species in activated human neutrophils: lipid metabolites of 2-chlorohexadecanal. J Lipid Res 51:1085-92
Ford, David A (2010) Lipid oxidation by hypochlorous acid: chlorinated lipids in atherosclerosis and myocardial ischemia. Clin Lipidol 5:835-852
Brahmbhatt, Viral V; Albert, Carolyn J; Anbukumar, Dhanalakshmi S et al. (2010) {Omega}-oxidation of {alpha}-chlorinated fatty acids: identification of {alpha}-chlorinated dicarboxylic acids. J Biol Chem 285:41255-69
Lankalapalli, Ravi S; Eckelkamp, Joseph T; Sircar, Debajit et al. (2009) Synthesis and antioxidant properties of an unnatural plasmalogen analogue bearing a trans O-vinyl ether linkage. Org Lett 11:2784-7